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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are 
notoriously challenging for treatment. Hyperactive nuclear factor κB (NF-κB) is a 
common culprit in both cancers. Previously, we discovered that protein arginine 
methyltransferase 5 (PRMT5) methylated and activated NF-κB. Here, we show that 
PRMT5 is highly expressed in PDAC and CRC. Overexpression of PRMT5 promoted 
cancer progression, while shRNA knockdown showed an opposite effect. Using an 
innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-
LL-CM01, which exhibited robust tumor inhibition effects in both cancers. An in silico 
structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its 
active pocket. Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the 
commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC. This study clearly 
highlights the significant potential of PRMT5 as a therapeutic target in PDAC and 
CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development 
in the future.
INTRODUCTION
Gastrointestinal cancer refers to malignant 
conditions of the gastrointestinal tract (GI tract) and 
accessory organs of digestion. Among them, pancreatic 
ductal adenocarcinoma (PDAC) and colorectal cancer 
(CRC) are two of the most challenging cancer types. 
For instance, PDAC has a very poor prognosis with a 
median survival between 6-8 months [1, 2] and ~8% of 
5-year survival rate. According to the American Cancer 
Society, PDACs represent the majority of the pancreatic 
cancer cases. The available options for treatment are 
hardly adequate in improving the quality of life of PDAC 
patients. Current therapy mainly consists of surgery, if 
diagnosed in the early stages. In more advanced stages, 
combined local treatment of radiation therapy and drugs 
such as gemcitabine plus nab-paclitaxel or FOLFIRINOX 
(combination of 5-flurouracil, leucovorin, irinotecan and 
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oxaliplatin) are used [3]. However, in addition to having a 
number of side effects, these therapeutic strategies barely 
increase the life span of the patient and provide little 
chance for a cure.
Equally devastating, CRC is the second leading 
cause of death in men and women combined in the United 
States [4]. It results from a series of genetic and epigenetic 
changes in colon epithelial cells, with successive mutations 
that accumulate over time [5]. Despite important advances 
in recent years, more than 40% of CRC patients will 
experience disease recurrence following primary therapy. 
The fact that there is currently “no cure” for a significant 
portion of patients with metastasis at the time of diagnosis 
creates a large medical need and an urgent demand for 
the discovery of effective therapeutic targets and new 
medicine for CRC treatment.
An important common feature of both PDAC [6-
8] and CRC [9-11] is the hyperactive nuclear factor κB 
(NF-κB) activity [12]. NF-κB is a critical eukaryotic 
transcription factor whose family consists of five 
members: RelA (p65), RelB, cRel, NF-κB1 (p50 and 
precursor p105), and NF-κB2 (p52 and precursor p100) 
[13]. Among these, the p65:p50 heterodimer is a prototype. 
NF-κB signaling can be classified into canonical and non-
canonical pathways. The canonical pathway has been well 
established as a key contributor to development of both 
PDAC [14, 15] and CRC [16, 17]. In this pathway, the 
inhibitor of κB (IκBα) sequesters the p65:p50 heterodimer 
in an inactive state in the cytoplasm. Upon receiving 
extracellular signals such as pro-inflammatory cytokines, 
etc., IκB kinase phosphorylates IκBα, leading to its 
degradation, the release of the p65:p50 complex, and the 
activation of NF-κB target genes [18]. A number of these 
downstream NF-κB target genes have been implicated in 
cancer. Increased NF-κB activation is not only associated 
with poor disease prognosis, but also with developing 
resistance against chemotherapy in PDAC and CRC [19, 
20]. Thus, controlling NF-κB activity is critical to the 
treatment of PDAC and CRC.
Recently, we became the first to discover that the 
protein arginine methyltransferase 5 (PRMT5) serves as 
a potent activator of NF-κB via dimethylating arginine 30 
of its p65 subunit [21]. The nature of PRMT5 as a histone 
modifying enzyme makes it an important therapeutic target 
to pursue. As a member of the family of PRMTs, PRMT5 
methylates arginine residues by catalyzing the transfer of 
methyl groups from a ubiquitous co-factor—S-adenosyl-
l-methionine (SAM) to specific arginine residues on their 
target proteins, leading to the symmetric dimethylation of 
its substrates [22-24].
In these studies we provide the first evidence that 
PRMT5 is highly overexpressed in PDAC and CRC. 
Overexpression of PRMT5 promoted cancer progression 
through increased activation of NF-κB, cell growth, 
anchorage-independent growth and cell migration in 
both PDAC and CRC. Importantly, we developed a 
PRMT5-specific AlphaLISA HTS technique (Amplified 
luminescent proximity homogeneous assay-linked 
immunosorbent assay high throughput screen) by which 
we identified a novel small-molecule inhibitor of PRMT5, 
PR5-LL-CM01. We showed that PR5-LL-CM01 is much 
more potent than the only commercial PRMT5 inhibitor, 
EPZ015666 [25]. Treatment with PR5-LL-CM01 led to a 
decrease in the activation of NF-κB and tumor progression 
in both PDAC and CRC. Using in silico modeling, we 
proposed that PR5-LL-CM01 inhibits the activity of 
PRMT5 by direct binding to the glutamate 444 (Glu444) 
residue in the active pocket of PRMT5 [26]. 
Here, we define for the first time a significant role 
of PRMT5 as a tumor promoter in PDAC and CRC. 
By discovering our leading compound PR5-LL-CM01 
with the AlphaLISA HTS technique, we proved that 
PRMT5 is a promising therapeutic target in PDAC and 
CRC. Of extreme importance and significance, PR5-LL-
CM01 could serve as an important basis for new drug 
development in PDAC and CRC.
RESULTS
PRMT5 is overexpressed in PDAC and CRC
In order to determine whether PRMT5 is a tumor 
promoter in PDAC and CRC, we first examined PRMT5 
expression in both cancers by Western blotting and 
immunohistochemistry (IHC) assay. As shown in Figure 
1A (left panel), PRMT5 was highly expressed in PDAC 
cells (AsPC1, MiaPaCa2 and PANC1) as compared to 
human normal pancreas HPNE cells. Tissue microarray 
(TMA) was further detected for PRMT5 expression 
using IHC assay. We showed that PRMT5 expression 
was significantly higher in various stages of PDAC, and 
particularly in the metastatic stage, as compared to the 
normal PDAC adjacent tissue (Figure 1A, right panel, 
and Supplementary Figure S1A). Similar experiments 
were carried out in a series of CRC cells (HT29, HCT116 
and DLD1), with normal colon FHC cells as the control. 
Again, we observed that PRMT5 is highly expressed in 
CRC cells (Figure 1B, left panel). Moreover, IHC assay 
of CRC TMA also indicated that PRMT5 had much higher 
expression in samples ranging from inflammation, polyp, 
to the metastatic stage of CRC as compared to adjacent 
normal tissue (Figure 1B, right panel, and Supplementary 
Figure S1B). These data clearly demonstrated that PRMT5 
is substantially overexpressed in both PDAC and CRC.
PRMT5 promotes cell proliferation, anchorage-
independent growth and cell migration in PDAC 
and CRC cells
Since PRMT5 is highly expressed in PDAC and 
CRC, we wondered whether it serves as a tumor promoter 
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in these cancers. In order to test this possibility, we 
examined the effect of PRMT5 on various characteristics 
of cancer cells including cell proliferation, anchorage-
independent growth, and cell migration. Stable cells with 
either PRMT5 overexpression or shRNA knockdown were 
established in PANC1 (PDAC) and HT29 (CRC) cells. 
Western blotting was conducted to confirm the expected 
PRMT5 expression in these cells (Figure 2A). Using these 
cells, we further showed that overexpression of PRMT5 
promoted cell growth, while shRNA knockdown reduced 
this effect in both PDAC and CRC cells (Figure 2B), 
strongly suggesting that PRMT5 is the promoter for cell 
proliferation in these cells.
Moreover, we conducted an anchorage-independent 
growth assay in soft agar. Data suggested that PRMT5 
overexpression led to a dramatic increase in both the 
colony size and number in PANC1 and HT29 cells (Figure 
2C), while shPRMT5 knockdown significantly reduced 
this ability, confirming the critical role that PRMT5 plays 
in promoting anchorage-independent cell growth in PDAC 
and CRC.
Another well-known property of cancer cells is 
the strong migration ability, which is critical for tumor 
invasion and metastases (31). As observed in Figure 2D, 
Boyden chamber assays were conducted, demonstrating 
that overexpression of PRMT5 substantially increased the 
number of migrated cells, whereas shPRMT5 knockdown 
showed quite opposite effect, pointing out the pivotal role 
that PRMT5 plays in the migratory ability of both PDAC 
and CRC. 
Collectively, the above data provided strong 
evidence regarding the overall tumor promoting ability of 
PRMT5 in both PDAC and CRC.
Using the innovative AlphaLISA HTS screen to 
discover a novel PRMT5 inhibitor PR5-LL-CM01 
Based on the above observations, we hypothesize 
that inhibition of PRMT5 with small-molecule inhibitors 
has potential therapeutic implications in PDAC and CRC. 
In order to successfully perform the HTS screen, we 
adapted the AlphaLISA technique (PerkinElmer) into an 
assay that could precisely quantify PRMT5 methylation of 
its substrate in a 384-well HTS platform. Compared to the 
conventional methods such as time resolved fluorescence 
energy transfer (TR-FRET) assay, the AlphaLISA 
technology is proved to be more sensitive, reliable, and 
adaptable for performing large-scale reactions. Thus it 
proves to be a more robust assay to be used for screening 
Figure 1: PRMT5 is overexpressed in pancreatic and colorectal cancer. A. and B. (Left panels), Western blots, showing that  A. 
PRMT5 expression is higher in PDAC cells (AsPC1, MiaPaCa2 and PANC1) as compared to control pancreatic cells HPNE. B. PRMT5 
expression is higher in CRC cells (HT29, HCT116 and DLD1) as compared to control colon cells FHC. β-actin was used as a loading 
control. A. and B. (Right panels), IHC staining, showing that A. PRMT5 expression was higher in PDAC tumor tissues as compared to the 
normal tissue. B. PRMT5 protein expression was higher in the inflammation, polyp, advanced stages of CRC and the metastatic stage as 
compared to the normal colon tissue.
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as compared to other methods used in the past [32,33]. 
To date, AlphaLISA has never been used for screening of 
PRMT5 inhibitors in the HTS format. We have overcome 
obstacles to successfully modify this technique from 
bench scale to a condition that can provide robust results 
in a robotic system. As shown in Figure 3A, PRMT5 
transferred the methyl groups from its methyl donor SAM 
to biotin-histone H4 peptide, leading to its symmetric 
dimethylation, which was recognized by the Acceptor 
beads conjugated with the anti-H4R3me2 antibody and 
the streptavidin tagged Donor beads. Upon excitation with 
light, emitted signal was detected by an EnVision® Reader, 
which was proportional to the amount of dimethylated 
H4R3. Therefore, for any small-molecule inhibitor used to 
inhibit the activity of PRMT5, a reduced signal emission 
would be detected.
The PRMT5 enzyme used in our screen was purified 
by conducting co-immunoprecipitation with anti-Flag 
beads in a 293-PRMT5-Flag cell line established by us 
(Figure 3B, top panel). This enzyme prep is highly active, 
with a near 7-fold increase of Alpha signal as compared 
to that of negative control (Figure 3B, bottom panel). Z’ 
factor, a statistical parameter for the robustness of the 
AlphaLISA assay, was calculated to be 0.6 (Figure 3B, 
bottom panel). An assay with a Z’ value > 0.5 is widely 
considered to be sensitive enough for a successful HTS 
[34]. Therefore, this test confirmed that our adapted 
PRMT5-specific AlphaLISA HTS technique was sensitive, 
robust, and successful.
We screened a library with 10,000 small 
molecules. A representative 384-well plate in the 
HTS (Supplementary Figure S2) shows a potential hit 
highlighted in red, with a significant decrease observed 
in the AlphaLISA signal, as compared to that with no 
inhibitor. Several top hits were identified and confirmed 
using both AlphaLISA and MTT assay in PDAC and CRC 
cells. Among these, the leading compound was PR5-LL-
CM01. PR5-LL-CM01 consists of a pyrozolo-pyrimidine 
core and three peripheral A, B and C groups (Figure 3C). 
We confirmed that the IC50 of PR5-LL-CM01 was 7.5 μM 
by the AlphaLISA approach (Figure 3D). Furthermore, 
in order to check the specificity of PR5-LL-CM01 to 
PRMT5, we generated PR5-LL-IEC01, a structural 
analog of PR5-LL-CM01 (Supplementary Figure S3A). 
The IC50 of PR5-LL-IEC01 was calculated to be 118μM 
by AlphaLISA (Supplementary Figure S3B), about 16-fold 
higher than that of PR5-LL-CM01 (Figure 3D), affirming 
that the inhibition of PRMT5 methyltransferase activity 
observed by AlphaLISA assay was specific to small-
molecule inhibitor PR5-LL-CM01. 
Moreover, we examined the inhibition by PR5-LL-
CM01 against other PRMT family members using the 
Figure 2: PRMT5 is important for cell proliferation, anchorage-independent growth and migration of PDAC and CRC. 
A. Western blot, confirming stable PRMT5 overexpression and shPRMT5 knockdown in PANC1 and HT29 cells. B. Cell proliferation assay, 
showing that cell proliferation was significantly higher in the WT-PRMT5 cell lines, while shPRMT5 cells exhibited quite opposite effect in 
both PANC1 and HT29 cell lines. C. Anchorage-independent growth assay, showing that anchorage-independent growth was significantly 
higher in the WT-PRMT5 cell lines, while dramatically reduced in the shPRMT5 cells. Both colony size and number are quantified at 
the bottom of the corresponding panels. The data represent the means ± standard deviation (S.D.) for three independent experiments. 
*P < 0.05 vs. control (Ctrl) group. D. Cell migration assay, showing that cell migration was significantly higher in the WT-PRMT5 
overexpression cells, while significantly reduced in the shPRMT5 cells. Upper panels, representative pictures in 20X magnification. Lower 
panel, quantification for the change in migration. The data represent the means ± S.D. for three independent experiments. *P < 0.05 vs. Ctrl.
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HotSpot radioisotope-based platform (Reaction Biology 
Corp) [35]. As shown in Supplementary Figure S4, these 
PRMTs showed zero effect, or at least a 10-fold higher 
IC50 than that of PRMT5, indicating the high specificity of 
PR5-LL-CM01 for PRMT5.
We previously found that PRMT5 activated NF-κB 
through methylation of its p65 subunit [21], therefore, 
we sought to determine whether treatment with PR5-LL-
CM01 would reduce p65 methylation. Accordingly, 293 
cells engineered to overexpress Flag-p65 were treated 
with 20μM PR5-LL-CM01 for 24hrs. Flag-p65 was 
pulled down with anti-Flag-M2 beads and analyzed with 
Western blot by probing with anti-dimethylated arginine 
antibody (Figure 3E). Compared to the untreated control 
cells, treatment with PR5-LL-CM01 significantly inhibited 
PRMT5-mediated p65 methylation. Collectively, the 
above experiments demonstrated that we have successfully 
developed a PRMT5-specific AlphaLISA HTS technique 
by which we discovered a novel PRMT5 inhibitor, PR5-
LL-CM01.
Figure 3: Discovery of PR5-LL-CM01 as a novel PRMT5 inhibitor through PRMT5-specific AlphaLISA HTS 
technique. A. Schematic illustration of the AlphaLISA technique. Biotinylated histone H4 is incubated with PRMT5 and methyl donor 
SAM. PRMT5 symmetrically dimethylates H4 on its arginine 3, a product that is recognized by Acceptor beads. Following the binding of 
Donor beads, the chemiluminescent signal is emitted and detected by the EnVision® Reader. The intensity of the Alpha signal is proportional 
to the PRMT5 activity. B. (Upper panel) Western blot, showing Flag-tagged WT-PRMT5 was overexpressed in the 293-WT-PRMT5-Flag 
cells as compared to the control 293 cells. 293-WT-PRMT5-Flag cells were used to purify PRMT5 for AlphaLISA assay. (Lower panel) 
Z’-plot of AlphaLISA assay, showing that Alpha signal with PRMT5 (red dots) is significantly higher than those without PRMT5 (blue 
dots). The mean values are represented with solid horizontal lines in the center of each sample group. Z’ value for our experiment was 0.6. 
C. Structure of PR5-LL-CM01, highlighting the core structure of a pyrozolo-pyrimidine group (red box), and three surrounding groups 
A, B and C, respectively. D. Calculation of IC50 of PR5-LL-CM01 using AlphaLISA, showing PR5-LL-CM01 concentration-dependent 
decrease of Alpha signal. The IC50 was ~7.5 μM. E. Co-IP-Western blot, showing that treatment with 20μM PR5-LL-CM01 inhibited p65 
methylation, a PRMT5 substrate, in 293-WT-p65-Flag cells. Flag beads were used to pull down WT-p65-Flag and samples were probed 
with anti-symmetric dimethyl arginine motif Ab (sdme-RG Ab). 
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PR5-LL-CM01 is a potent inhibitor of PRMT5 in 
vitro
In order to determine the efficacy of PR5-LL-
CM01, we used both PDAC and CRC cells as the in 
vitro models. Recently, Chan-Penebre et al. identified 
a PRMT5 inhibitor, EPZ015666 and showed its high 
efficacy in inhibiting PRMT5 in mantle cell lymphoma 
disease models [25]. We wondered whether EPZ015666 
would be effective in PDAC and CRC. Both PDAC and 
CRC cells were treated with increasing concentrations 
Figure 4: PR5-LL-CM01 is a potent inhibitor of PRMT5 in PDAC and CRC cells. A. MTT assay in PDAC cells (PANC1, 
MiaPaCa2 and AsPC1), showing that cell viability decreased significantly in presence of increasing concentrations of PR5-LL-CM01. B. 
MTT assay in CRC cells (HT29, HCT116, and DLD1), showing dramatic decrease of cell viability in presence of increased concentrations 
of PR5-LL-CM01. C. Table, summarizing the IC50 values for PR5-LL-CM01 in PDAC and CRC cells, respectively.
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of PR5-LL-CM01 or EPZ015666, and quantified for 
cell viability with the MTT assay. We showed that PR5-
LL-CM01 had a range of IC50 at 2-4 µM in PDAC cells 
(PANC1, MiaPaCa2 and AsPC1) (Figures 4A, 4C), and a 
range of IC50 at 10-11 µM in CRC cells (HT29, HCT116 
and DLD1) (Figure 4B, 4C). However, EPZ015666 was 
much less effective as compared to PR5-LL-CM01, with a 
range of IC50 at 50-95 µM for PDAC cells, and a range of 
IC50 at 180-195 µM for CRC cells (Supplementary Figure 
S5). Therefore, our data suggested that PR5-LL-CM01 is 
a more potent PRMT5 inhibitor than EPZ015666 in PDAC 
and CRC cells.
Additionally, as compared to cancer cell lines, the 
respective normal control cells had a much higher survival 
at the IC50 observed in their cancer cell line counterparts 
(Supplementary Table 1). HPNE and FHC are the normal 
pancreatic and colon control cell lines respectively, that 
were used in the present study. This suggested that PR5-
LL-CM01 had higher efficacy to specifically inhibit cancer 
cells and demonstrated low toxicity in normal cells.
In addition, we determined the IC50 of the inactive 
structural analog PR5-LL-IEC01 in PANC1 and HT29 
cells using the MTT assay. Not surprisingly, we observed 
remarkably less potency of PR5-LL-IEC01 to decrease the 
cell viability in these lines, with an IC50 of over 14-40-fold 
higher (Supplementary Figure S6) than that of PR5-LL-
CM01 (Figures 4A and 4B) in the same cell lines.
Next, we used the anchorage-independent assay 
described previously to check if treatment with PR5-LL-
CM01 affected colony formation of either PDAC or CRC 
cells. We observed that treatment with PR5-LL-CM01 
strongly inhibited colony forming ability in both PANC1 
and HT29 cells (Supplementary Figure S7). 
In light of recent work suggesting 3D spheroidal 
cell culture may closely mimic the in vivo tumor 
microenvironment such as having a hypoxic core, 
decreased cell-cell contact and greater survival [36, 37], 
we determined the efficacy of PR5-LL-CM01 against 3D 
spheroids of PDAC and CRC cells (Supplementary Figure 
S8). With increasing concentrations of PR5-LL-CM01, 
we observed a dosage-dependent decrease in the ability 
of both PANC1 and HT29 cells to form 3D spheroids 
in culture, highlighting the tumor-inhibiting potential of 
PR5-LL-CM01 in vitro.
Figure 5: Treatment with PR5-LL-CM01 significantly inhibited NF-κB activation in PDAC and CRC cells. A. NF-κB 
luciferase assay, showing that overexpression of WT-PRMT5 led to NF-κB activation, while shPRMT5 resulted in quite opposite effect in 
both PANC1 and HT29 cells. *P < 0.05 vs. Ctrl. B. Luciferase assay, showing a decrease in NF-κB activation with increasing concentrations 
of PR5-LL-CM01 in PANC1 (left panel) and HT29 cells (right panel). A much higher concentration of EPZ015666 is needed in order to 
reach similar level of NF-κB inhibition as that of PR5-LL-CM01. The data represent the means ± S.D. for three independent experiments. 
*P < 0.05 vs. Untreated group. C. qPCR analysis, showing that overexpression of PRMT5 significantly enhanced IL-1β-triggered NF-κB 
target genes (TNFα and IL8) expression, while shPRMT5 exhibited quite opposite effect, in both PANC1 and HT29 cells. *P < 0.05 vs. 
Ctrl; #P < 0.05 vs. Ctrl+IL-1β-treated group. D. qPCR analysis, showing that treatment with PR5-LL-CM01 dramatically decreased TNFα 
and IL8 expression, in both PANC1 and HT29 cells. The data represent the means ± S.D. for three independent experiments. *P < 0.05 vs. 
Untreated group.
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PR5-LL-CM01 inhibited NF-κB activation and its 
target gene expression in PDAC and CRC cells
Previously, we discovered that PRMT5 activates 
NF-κB through methylation of its p65 subunit in HEK293 
cells [21]. In Figure 5A, by using a κB luciferase assay, 
we confirmed that overexpression of PRMT5 significantly 
enhanced NF-κB activity, while shPRMT5 knockdown 
exhibited a quite opposite effect. Next, we determined 
the effect PR5-LL-CM01 on NF-κB activation. As shown 
in Figure 5B, treatment with increasing concentrations 
of PR5-LL-CM01 resulted in a corresponding decrease 
in NF-κB activation in PANC1 and HT29 cells. In great 
contrast, a much higher concentration of EPZ015666 
was required to observe a similar effect (Figure 5B), 
demonstrating the much higher efficacy of PR5-LL-CM01 
to decrease the NF-κB activation in PDAC and CRC cells. 
Moreover, treatment with inactive analog PR5-LL-IEC01 
had no significant effect on the NF-κB activation in both 
PDAC and CRC cells, indicating the specificity of PR5-
LL-CM01 to decrease NF-κB activation in these cell lines 
(Supplementary Figure S9).
We previously showed that PRMT5-mediated NF-
κB activation led to the induction of typical NF-κB target 
genes, such as tumor necrosis α (TNFα) and interleukin 
8 (IL8) in 293 cells. We therefore wondered whether an 
upregulation of these genes is observed in PDAC and CRC 
cells. Quantitative PCR showed that upon stimulation with 
IL-1β, there was a substantial increase in the expression 
of TNFα and IL8 in PRMT5 overexpressing cells, while 
a dramatic reduction was observed upon shPRMT5 
knockdown, in both PANC1 and CRC cells (Figure 5C). 
Treatment with PR5-LL-CM01 also led to a significant 
decrease in both genes (Figure 5D), thus indicating that 
PR5-LL-CM01 decreased the PRMT5-mediated NF-κB-
dependent gene activation. Overall, we demonstrated 
that PR5-LL-CM01 had significant efficacy in inhibiting 
NF-κB activation and its downstream gene expression in 
PDAC and CRC cells.
PR5-LL-CM01 has dramatic anti-tumor efficacy 
in vivo
Since we have shown that PR5-LL-CM01 had 
great anti-cancer efficacy in PDAC and CRC cells in 
vitro, we wonder whether PR5-LL-CM01 exhibits tumor 
inhibition effect in vivo. Either PANC1 or HT29 cells were 
subcutaneously xenografted into NOD scid gamma (NSG) 
Figure 6: PR5-LL-CM01 displayed significant anti-tumor effect in vivo. A. No significant changes in body weight were 
observed over the course of treatment in either PANC1 or HT29 model after treatment with 20mg/kg of PR5-LL-CM01. (*P < 0.05, n = 
4). B. Tumor efficacy study for PANC1 or HT29 cells which were subcutaneously implanted in NSG mice. Inhibition of tumor growth was 
observed upon treatment with 20mg/kg of PR5-LL-CM01 intraperitoneally for 3X/week, as compared to the vehicle control. (*P < 0.05, 
n = 4).
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mice and then treated with PR5-LL-CM01 three times per 
week at 20mg/kg till the day the mice were sacrificed. 
Both body weight and tumor size were monitored during 
this process. As shown in Figure 6A, injection of PR5-
LL-CM01 did not visibly affect the mice body weight. 
However, it led to significant tumor inhibition in both 
PANC1 and HT29 (Figure 6B) xenografted mice, 
demonstrating the strong anti-tumor efficacy of PR5-LL-
CM01 in both PDAC and CRC.
Structural modeling of binding interactions 
between PR5-LL-CM01 and PRMT5
In order to visualize the binding of PR5-LL-CM01 
with PRMT5, we employed structural modeling approach 
using the existing information of PRMT5 crystal structure 
[26]. PR5-LL-CM01 was docked in the presence (SAM-
bound) or absence of SAM (Apo-PRMT5). Under SAM-
bound condition (Figure 7A, left panel), the binding sites 
for PR5-LL-CM01 and EPZ015666 on PRMT5 overlap 
to a great extent, indicating that these two inhibitors 
probably interact with PRMT5 through largely similar 
group of binding sites. However, in the Apo-PRMT5 
condition, though the binding sites of EPZ015666 remain 
the same as those in SAM-bound condition, the binding 
position of PR5-LL-CM01 shifted dramatically from its 
original binding position in the SAM-bound condition 
to the new position (pink dotted line, Figure 7A, right 
panel), which is, intriguingly, same as the SAM binding 
position in the SAM-bound condition (Figure 7A, left 
panel). This interesting phenomenon suggest that PR5-LL-
CM01 could possibly interfere with the residues involved 
in SAM binding to PRMT5 in SAM-bound PRMT5, but 
can also block the binding of SAM to Apo-PRMT5 by 
occupying the similar binding site for SAM. In contrast, 
EPZ015666 binding stayed the same in both SAM-bound 
or Apo-PRMT5 conditions, thus binding to PRMT5 in 
a completely independent manner from SAM, which is 
consistent with previously published data [25]. In addition, 
we showed that both binding events under SAM-bound 
Figure 7: In silico prediction of the binding of PR5-LL-CM01 and EPZ015666 to PRMT5. A. left panel, In SAM (purple 
color)-bound condition, the binding sites for PR5-LL-CM01 (turquoise color) and EPZ015666 (orange color) on PRMT5 overlap to a great 
extent, suggesting that these two compounds inhibit PRMT5 through largely similar group of binding sites. Right panel, in Apo-PRMT5 
condition, the binding of EPZ015666 remains the same as that in the left panel, however, PR5-LL-CM01 has shifted dramatically from 
its left panel’s position (red dotted line) to the new position (pink dotted line), which is same as SAM’s position in the left panel. B. Table, 
listing the binding affinities of PR5-LL-CM01-PRMT5 interactions in SAM bound and Apo-PRMT5 conditions. PR5-LL-CM01 showed 
favorable binding energies under both conditions, with Apo-PRMT5 condition having a slightly stronger binding affinity (-7.911 kcal/
mol). C. Ligand affinity map in the SAM-bound condition, depicting the PRMT5 residues interacted with PR5-LL-CM01. Different bonds 
or charges are symbolized on the right side of the figure. Key site, Glu444, is circled in red dotted line. D. Binding residue distribution 
diagram, illustrating the PRMT5 residues that potentially bind to PR5-LL-CM01 alone (red font), EPZ015666 alone (blue font), or both 
(green font). E. Hypothetical model, proposing that PRMT5 overexpression promotes cancer phenotype, whereas inhibition using PR5-LL-
CM01 impedes PDAC and CRC progression by inhibiting NF-κB activation.
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or Apo-SAM conditions are energetically favorable, with 
the Apo-PRMT5 (-7.911 kcal/mol) being slightly more 
favorable than the SAM-bound condition (-6.949 kcal/
mol) (Figure 7B). A ligand binding affinity map (Figure 
7C) further depicts the PRMT5 residues that interact with 
PR5-LL-CM01 in the SAM-bound condition. Importantly, 
PR5-LL-CM01 forms a hydrogen bond with the Glu444 
residue in the PRMT5 active pocket. Since this residue 
is essential for the methyltransferase activity of PRMT5, 
this interaction points out yet another layer of important 
mechanism regarding how PR5-LL-CM01 may inhibit 
PRMT5 activity in addition to what we have proposed in 
Figures 7A and 7B.
As described in Figure 7A, under the SAM-
bound condition, PR5-LL-CM01 and EPZ015666 bind 
to PRMT5 in a largely overlapped region. To look at 
these sites in much more detail, we summarized these 
interactive residues in Figure 7D. The sites that can solely 
interact with PRMT5 by PR5-LL-CM01 are denoted in 
red, solely by EPZ015666 in blue, or by both in green. 
Most of the residues are present in the Rossman fold, 
followed by several residues in the β-barrel, and some 
residues in the linker domain of the PRMT5 structure. 
Since the methyltransferase domain is comprised within 
the Rossman and β-barrel domains, these evidences 
further support that PR5-LL-CM01 binds to residues in 
the catalytic domain of PRMT5. We show that in addition 
to a few commonly shared binding sites with EPZ015666, 
PR5-LL-CM01 largely exhibits its quite unique binding 
sites to PRMT5 (Figure 7D).
Taken together, we hypothesize that PRMT5 
overexpression can promote the cancer phenotype through 
PRMT5-mediated NF-κB activation, whereas using PR5-
LL-CM01 to block this activity could impede PDAC and 
CRC progression (Figure 7E). Therefore, PR-LL-CM01 
could serve as the drug development basis to treat PDAC 
and CRC in the very near future.
DISCUSSION
The White House Cancer Moonshot’s mission 
is to double the rate of progress in cancer research and 
treatment. Both PDAC and CRC are among the leading 
cause of cancer-related deaths in the United States. 
Despite important advances in recent years, many patients 
continue to experience disease recurrence following 
primary therapy. Moreover, there is currently “no cure” 
for a significant number of patients presenting with 
metastasis upon diagnosis. An estimated $20 billion will 
be spent on PDAC and CRC care in the United States in 
2016, reflecting the urgent medical need for the discovery 
of newer PDAC and CRC treatment options.
Post-translational modifications (PTMs) regulate 
protein function in eukaryotes and have been shown 
to play important roles in a variety of cancers [38]. 
Methylation of lysine and arginine is one of the most 
critical PTMs seen in nature. In this study, we are the 
first to show that PRMT5 expression was significantly 
upregulated in PDAC and CRC. Furthermore, increased 
expression of PRMT5 in cancer cells led to enhanced 
cancer-promoting characteristics, including cell 
proliferation, anchorage-independent growth, and cell 
migration, clearly highlighting the role of PRMT5 as a 
tumor promoter in PDAC and CRC.
NF-κB is a critical transcription factor that is 
hyperactivated in various cancers. Since it also plays a 
crucial role in normal cellular functioning, direct targeting 
of NF-κB has not proven to be a successful therapeutic 
approach [39]. These obstacles highlight the importance 
of identifying pathway-specific inhibition of NF-κB 
activity in cancer treatment. In this regard, the discovery 
of PRMT5-mediated activation of NF-κB and its targeted 
inhibition in PDAC and CRC is of great importance and 
significance. Furthermore, the successful development 
and application of the PRMT5-specific AlphaLISA 
HTS technique in this study constitutes another layer of 
unique contribution to the drug discovery field. Using 
this sensitive approach, we successfully identified PR5-
LL-CM01 as our leading hit and confirmed that it is a 
highly potent and specific PRMT5 inhibitor. Using a 
closely related structural analog, PR5-LL-IEC01, we 
demonstrated the specificity of the effect shown by PR5-
LL-CM01. Currently, EPZ015666 is the only specific 
PRMT5 inhibitor available on the market [25]. Chan et 
al. reported that EPZ015666 is very effective in inhibiting 
mantle cell lymphoma [25]. We showed that PR5-LL-
CM01 was ~10-15 fold more potent than EPZ015666 in 
PDAC and CRC models, making PR5-LL-CM01 the first 
PRMT5 inhibitor to be highly effective in the treatment of 
solid tumors. We speculate that PR5-LL-CM01 could be 
more effective than EPZ015666 in the treatment of other 
solid cancers with hyper PRMT5 expression. We are very 
eager to test this possibility in the very near future. 
Additionally, structural modeling experiments 
showed that PR5-LL-CM01 and EPZ015666 could 
interact with PRMT5 through quite different mechanisms. 
Particularly, PR5-LL-CM01 interacts with Glu444 
on PRMT5, a critical residue for the catalytic activity 
of PRMT5 [26]. Interestingly, we observed that all 
the residues participating in the binding interactions 
between PR5-LL-CM01 and PRMT5 span over the 
Rossman fold and β-barrel domains of PRMT5, which 
have been previously shown to comprise the catalytic 
methyltransferase domain of PRMT5 and the region 
where SAM and its substrates bind [26]. On the other 
hand, EPZ015666 binds to PRMT5 independent from 
SAM binding sites. These quite different PRMT5 binding 
mechanisms could shed light on why PR5-LL-CM01 is 
more potent than EPZ015666 in killing PDAC and CRC 
cells.
Of note, it is possible that PRMT5-mediated 
pathways are complicated. Though many mechanisms 
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of the tumor-promoting tendencies of PRMT5 are still 
unclear, the insights provided by this study are extremely 
valuable in understanding the workings of PRMT5. They 
could also possibly be applied to other cancers beyond 
PDAC and CRC. PRMT5 is upregulated in various types 
of cancers, including but not limited to pancreas, colon, 
breast, prostate, and lung cancers, as well as lymphoma 
and melanoma [40-44]. Due to the commonality of high 
levels of PRMT5, our current findings with regards to 
PDAC and CRC could have broader impacts on the 
understanding of cancer progression as a whole.
In summary, we have identified the significant role 
of PRMT5 as a tumor promoter in PDAC and CRC, as well 
as highlighted its potential to be exploited as an important 
therapeutic target. Building upon this exciting work, our 
immediate future plan would be to generate derivatives 
of PR5-LL-CM01 with the ultimate goal of moving this 
discovery to clinical application. In terms of how PR5-
LL-CM01 inhibits PRMT5, one line of research we would 
like to pursue is to further verify our in silico model with 
purified PRMT5 crystal for the structure analysis. We will 
also determine the direct binding of PR5-LL-CM01 and 
its derivatives to PRMT5 with isothermal calorimetry 
(ITC) experiments, a cutting-edge technique that is able 
to monitor direct binding of a ligand to a protein.
Overall, the discovery of PR5-LL-CM01 opens 
a door to promising new PDAC and CRC therapies and 
gateways to better understanding the workings behind 
PDAC and CRC as a whole. In the long run, we will move 
toward clinical trials with the few best-characterized PR5-
LL-CM01 derivatives with the ultimate goal of improving 
PDAC and CRC patient survivorship and treatment.
MATERIALS AND METHODS
Cell lines
Pancreatic control (HPNE) and cancer cell lines 
(PANC1, MiaPaCa2 and AsPC1) were a kind gift 
from Dr. Murray Korc (Indiana University School of 
Medicine). The normal colon cell line (FHC) and CRC 
(HT29, HCT116, DLD1) cell lines were purchased from 
the American Tissue Culture Collection. All pancreas-
derived cell lines were grown in Dulbecco’s Modified 
Eagle Medium (DMEM) (GE Healthcare), supplemented 
with 1% of penicillin/streptomycin, 10% fetal bovine 
serum (FBS). CRC cells were maintained in Roswell 
Park Memorial Institute Medium (RPMI 1640) (GE 
Healthcare), containing 1% penicillin/streptomycin and 
10% FBS, while FHC cells were cultured under the 
same condition with further addition of 25mM HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
10ng/ml cholera toxin, 0.005 mg/ml insulin, 0.005 mg/
ml transferrin and 100 ng/ml hydrocortisone. All cell lines 
were cultured at 37°C under 5% CO2 and used between 
passages 2 to 3. Cell lines were authenticated using 9 
Marker STR Profile.
Western blotting
Protein samples were run on a 10% polyacrylamide 
gel and then transferred overnight to a polyvinylidene 
fluoride (PVDF) membrane (Fisher Scientific) at 4°C. 
Primary antibodies for anti-PRMT5 (Abcam; ab109451), 
anti-Flag (Sigma-Aldrich; F1804), anti-dimethyl arginine 
motif (sdme-RG) (Cell Signaling Technology; 13222) and 
β-actin (Sigma-Aldrich; A5316) and their corresponding 
secondary antibodies were used. The enhanced 
chemiluminescent (ECL) detection method (PerkinElmer) 
was conducted to detect the protein signal.
Immunohistochemistry assay
Pancreatic and colon cancer tissue microarrays with 
matched normal adjacent controls were acquired from 
US Biomax Inc. The tissue microarrays were blocked 
using protein-blocking solution (Dako Corp.) for 30 min. 
All subsequent staining steps were performed using the 
Dako FLEX SYSTEM and an automated Immunostainer. 
Incubations were carried out at room temperature and 
Tris buffered saline containing 0.05% Tween 20, pH 7.4 
(Dako Corp.) was used for all the washes and diluents. 
Anti-PRMT5 primary antibody (Abcam; ab109451) 
was used to detect PRMT5 localization. Horseradish 
peroxidase-conjugated secondary antibody was then used, 
followed by addition of the chromogen, which formed 
a brown precipitate at the binding site of secondary 
antibody. Imaging was done using Aperio whole slide 
digital imaging system. The system imaged all slides at 
20X magnification.
Luciferase assay
The NF-κB luciferase construct p5XIP10 
(containing five tandem copies of the NF-κB site from the 
IP10 gene) [21] was transfected transiently in the cell lines 
using Lipofectamine and PLUS Reagents (Invitrogen). 
Luciferase activity was assayed 48 hrs later by using 
the Luciferase Assay System with Reporter Lysis Buffer 
kit (Promega) per the manufacturer’s instructions. The 
activity was measured using a Synergy H1 Multi-Mode 
Reader (BioTek Instruments Inc.).
Anchorage-independent assay
2.4% and 1.25% agar were used to prepare the 
bottom and top layers of the soft agar, respectively. The 
bottom agar was added to each well of a 6-well plate. 
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2X105 cells for each cell line were then mixed into top 
agar solution and layered on top of the bottom layer. The 
plates were incubated for 10-20 days at 37°C and 5% 
CO2. Images were captured using a Canon EOS Rebel T3i 
Digital SLR camera and quantification of colony size and 
number was performed using ImageJ.
Migration assay
Migration assay was conducted using Boyden 
chambers. 8μm pore size cell culture inserts (Corning) 
were placed in a 24-well plate. Each chamber was coated 
with gelatin on the side facing the lower chamber. 2X105 
cells were suspended in serum-starved media in the upper 
chamber of the well. Corresponding serum rich media was 
added to the lower chamber. Migrated cells were fixed 
using 4% formaldehyde followed by crystal violet staining 
and counting using a microscope at 20X magnification. 
The images were captured using a Canon EOS Rebel T3i 
Digital SLR camera.
AlphaLISA HTS screening
PRMT5 enzyme was purified with anti-Flag-M2 
beads (Sigma-Aldrich) from 293 cells with the 
overexpression of Flag-PRMT5 protein, as described 
previously [21]. The enzyme prep was diluted in assay 
buffer (30mM Tris, pH 8.0, 1mM DTT, 0.01% BSA, 0.01% 
Tween-20) before use. SAM (New England Biolabs) was 
used as the methyl group donor and unmethylated histone 
H4R3 (Anaspec) was used as a substrate. For screening, 
library compounds were added with the robotic system. 
All these components were incubated at room temperature 
(R.T.) for 1 hr. Acceptor beads and Donor beads were 
then diluted in 1X Epigenetics buffer (PerkinElmer) 
before use. Acceptor beads were then added at a final 
concentration of 20 μg/ml to the reaction mixture and the 
plate was incubated at R.T. for 1 hr. Donor beads were 
added at a final concentration of 20 μg/ml and the plate 
was incubated at R.T. for 30 min. The reaction was run in 
384-well plates. The plates were read using an EnVision® 
Reader.
Co-immunoprecipitation experiment
293 with stable overexpression of Flag-p65 protein, 
were treated with 20µM of PR5-LL-CM01 for 24 hrs. p65 
was then pulled down with anti-Flag-M2 beads, using 
immunoprecipitation methods as described previously 
[21]. The samples were then run on a 10% protein gel, 
and probed with anti-dimethyl arginine motif (sdme-RG) 
antibody (Cell Signaling Technology; 13222), to check for 
dimethylation levels of p65.
MTT [(3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide)] assay
Cells were seeded at 90% confluence in 96-well 
plates and titrated with different dosages of PR5-LL-
CM01 for 4 days. Media was then removed and 10μl of 
MTT (Sigma-Aldrich) was added per well. Cells were 
incubated for 2 hrs at 37°C before adding 100μl of DMSO 
to each well and quantified with the Synergy H1 Multi-
Mode Reader (BioTek Instruments Inc).
Quantitative PCR
Cells were cultured to 90% confluence and total 
RNA was isolated using Trizol as described previously 
[21]. cDNA was prepared by reverse-transcriptase PCR 
from total RNA using the SuperScript III First-Strand 
Synthesis System (Invitrogen). qPCR was carried out 
using FastStart Universal SYBR Green Master ROX 
(Roche). Primers were designed by Primer Express 3.0 
software and will be available upon request.
Tumor efficacy study
Male NSG mice were obtained from the In Vivo 
Therapeutics Core at Indiana University School of 
Medicine. After acclimation for 7 days, NSG mice (6-8 
weeks old) were xenografted with Mycoplasma-free 
PANC1 or HT29 cells subcutaneously (1 X 107 PANC1 
or 3 X 106 HT29 cells used per mouse in 0.2 ml of a 1:1 
mix of phosphate-buffered saline and Matrigel) (BD 
Biosciences). 5 mice were randomized in each group 
when tumor volumes reach ~100mm3. Mice were treated 
with either vehicle control or 20mg/kg of PR5-LL-CM01 
(drug stock dissolved in 1:1 Cremophor:ethanol solution) 
intraperitoneally 3 times per week . Tumor volumes and 
body weights were measured twice a week. The study was 
performed in accordance with the guidelines and standards 
of the Institutional Animal Care and Use Committee 
(IACUC) and under the approved animal protocol # 11066 
MD/R by Indiana University.
Structural analysis and docking experiments
For docking, chain A of PRMT5 protein in 4X61.
pdb from the Protein Databank was used. All docking 
experiments were performed by Glide program (version 
6.8) of the Schrodinger suite 2015-3 in standard precision 
mode [27, 28]. The protein was prepared for docking by 
the Protein Preparation Wizard of Schrodinger suite 2015-
3 [29]. Control docking experiment was performed by 
deleting the ligand PR5-LL-CM01 or EPZ015666 from 
the crystal structure while keeping the ligand SAM. The 
control docking experiment was able to reproduce the 
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binding pose of EPZ015666 seen in the crystal structure. 
An additional docking experiment was done by docking 
EPZ015666 into the PRMT5 active site after deleting the 
SAM ligand as well as EPZ015666 from the active site. 
PR5-LL-CM01 was docked into the PRMT5 active site 
in two separate docking experiments. In one experiment, 
the compound was docked into the PRMT5 active site in 
which EPZ015666 is deleted while SAM is kept. In the 
other experiment, PR5-LL-CM01 was docked into the 
completely empty active site in which SAM was deleted. 
All the figures for this experiment were prepared with 
Maestro version 10.3 [30].
Statistical analysis
Statistical analysis was performed using Prism 6 
software (GraphPad, San Diego, CA). Results have been 
presented as mean ± SD or mean ± SEM, as specified. A 
two-tailed Student’s t test was used while comparing two 
means to test for significant differences. All statistics were 
calculated on triplicate experiments and p value < 0.05 
was considered statistically significant. 
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